
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
What is the first thing you share with your patient when you are about to prescribe a new medication?
In this episode of The Big Q, Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, shares how he introduces new medications to patients, from indications to possible adverse effects.
Dr Tampi is professor and chairman, Department of Psychiatry, Creighton University School of Medicine and Catholic Health Initiatives (CHI) Health Behavioral Health Services, Omaha, Nebraska. He is also an adjunct professor of psychiatry at Yale School of Medicine.




